You are here

Our science / Clinical Trials / Find a Trial / NCT01302080

Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)

Back to Search Print Save as PDF Bookmark Trial

NCT01302080

Last updated on October 20, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Harmonex Neuroscience Research
Dothan, Alabama, 36303 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obsessive Compulsive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-16 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Children age 6 to 16 (inclusive) with anxiety, depression, or obsessive-compulsive
disorder, receiving treatment in outpatient setting, and who are prescribed a new
prescription for sertraline to treat one of the above study-qualifying disorders or
beginning psychotherapy for same.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Psychotic at study entry

- Diagnosis of bipolar disorder

- Diagnosis of schizoaffective or schizophrenia

- Anorexia

- Bulimia or eating disorder not otherwise specified (NOS)

- Autism

- Pervasive developmental disorder

- High risk of suicide within 2 weeks of initiating study treatment

- Significant mental retardation

NCT01302080
Pfizer
Active, not recruiting
Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search
Descriptive Information
Brief TitleSertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
Official TitleSPRITES: SERTRALINE PEDIATRIC REGISTRY FOR THE EVALUATION OF SAFETY A NON-INTERVENTIONAL, LONGITUDINAL, COHORT STUDY TO EVALUATE THE EFFECTS OF LONG-TERM SERTRALINE TREATMENT IN CHILDREN AND ADOLESCENTS
Brief SummaryTo evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) with a diagnosis of anxiety disorder, depressive disorder or obsessive compulsive disorder.
Detailed DescriptionPurposive sample: patients are not randomly selected, that is, he or she must meet certain inclusion criteria in order to qualify as a potential study participant.
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationThe accessible population is children meeting inclusion/exclusion criteria from US centers in various clinical settings, including the Child and Adolescent Psychiatry Trials Network (CAPTN). From these, the study-eligible population (all children age 6 to 16 (inclusive) with an anxiety, depressive, or obsessive-compulsive disorder, who are exposed to sertraline under real-world conditions) will comprise an inception cohort of enrolled subjects beginning treatment for one of the study-qualifying disorders with sertraline or psychotherapy.
ConditionObsessive Compulsive Disorder
Intervention
  • Drug: sertraline
    Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
  • Behavioral: psychotherapy
    Non-interventional study- as above
Study Groups/Cohorts
  • Sertraline-treated
    inception cohort of enrolled subjects beginning treatment for one of the study qualifying disorders with sertraline
    Intervention: Drug: sertraline
  • pyschotherapy only
    inception cohort of enrolled subjects beginning treatment for one of the study qualifying disorders with psychotherapy
    Intervention: Behavioral: psychotherapy
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusActive, not recruiting
Actual Enrollment
 (submitted: October 12, 2017)		941
Original Estimated Enrollment
 (submitted: February 18, 2011)		900
Estimated Study Completion DateOctober 2020
Estimated Primary Completion DateOctober 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Children age 6 to 16 (inclusive) with anxiety, depression, or obsessive-compulsive disorder, receiving treatment in outpatient setting, and who are prescribed a new prescription for sertraline to treat one of the above study-qualifying disorders or beginning psychotherapy for same.

Exclusion Criteria:

  • Psychotic at study entry
  • Diagnosis of bipolar disorder
  • Diagnosis of schizoaffective or schizophrenia
  • Anorexia
  • Bulimia or eating disorder not otherwise specified (NOS)
  • Autism
  • Pervasive developmental disorder
  • High risk of suicide within 2 weeks of initiating study treatment
  • Significant mental retardation
Sex/Gender
Sexes Eligible for Study:All
Ages6 Years to 16 Years   (Child)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesUnited States
Removed Location Countries  
 
Administrative Information
NCT NumberNCT01302080
Other Study ID NumbersA0501093
SPRITES ( Other Identifier: Alias Study Number )
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da....
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2018

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now